Provided by Tiger Trade Technology Pte. Ltd.

Fractional Shares

2,020.88
+16.530.82%
Number of Gainers:615
Number of Losers:390
Number of Flat:16
PE:- -
High:2,028.19
Open:2,004.58
Low:2,004.58
Close:2,004.35
Volume:6.06B
Turnover:742.41B
Market Cap:96.59T
Float Cap:90.42T

Loading ...

Press Release: First Trust Advisors L.P. Announces Distribution for First Trust Enhanced Short Maturity ETF

Dow Jones
·
Sep 30

Odds of an October Rate Hike Slip to 50%, Fed's No. 2 Official Says One More Increase Is Needed This Year but There Is No Rush

Deep News
·
Sep 30

American Airlines, Alaska Airlines Plan to Add Alaska to Atlantic, Pacific Joint Businesses

Reuters
·
Sep 30

Shares of Workday Flat in Extended Trade After Co Announces Workforce Reduction

THOMSON REUTERS
·
Sep 30

Kroger Co - Offers $650 Mln 5.800% Notes Due 2032 and $850 Mln 6.200% Notes Due 2036 - SEC Filing

THOMSON REUTERS
·
Sep 30

FingerMotion Signs Deal to Buy Newbit Technology for Us$2.3 Million Cash

Reuters
·
Sep 30

Concentrix Q3 2026 Net Loss Widens to $988.11 Million; Revenue Falls to $2.45 Billion

Reuters
·
Sep 30

Equillium Posts New Preclinical EQ504 Data in Ulcerative Colitis at International AHR Conference

Reuters
·
Sep 30

Larimar Therapeutics Names John Harlow President and COO

Reuters
·
Sep 30

Talen Names Terry Nutt CEO Effective Jan. 1, 2027; Mac McFarland Retires at Year-End

Reuters
·
Sep 30

Dyne Therapeutics Posts One-Year Phase 1/2 Achieve Data Showing Functional Gains for DYNE-101 in DM1

Reuters
·
Sep 30

Republic Services Updates Financial Calendar for Third-Quarter Earnings Release and Investor Call

Reuters
·
Sep 30

Applied Materials and Kioxia Partner at the Epic Center to Advance Next-Generation Memory Technology

THOMSON REUTERS
·
Sep 30

GF Names Robert Downie VP of US Sales for Building Flow Solutions Americas

Reuters
·
Sep 30

Dyne Therapeutics, - Expects Topline Data from Achieve Rec in Q1 2027 with Primary Endpoint Vhot at 6 Months

THOMSON REUTERS
·
Sep 30

Dyne Therapeutics, - Reports Improvement at 6 Months in Vhot with Z-Basivarsen in Dm1

THOMSON REUTERS
·
Sep 30

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 Achieve Trial of Z-Basivarsen (Dyne-101) for Myotonic Dystrophy Type 1 (Dm1)

THOMSON REUTERS
·
Sep 30

FingerMotion Enters Definitive Agreement to Acquire 100% of Newbit Technology Inc., Securing the 9.9 MW County of Newell Powered Site

GlobeNewswire
·
Sep 30

What is a Public Benefit Corporation, the Anthropic Legal Structure?

Reuters
·
Sep 30

Workday Reorganizes Teams, Cuts Workforce About 2.5%

Reuters
·
Sep 30